Unknown

Dataset Information

Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial.


ABSTRACT:

Background

The social stigma and chronicity of psoriasis significantly affect health-related quality of life (HRQoL).

Objective

We examined the effect of three regimens of secukinumab on HRQoL in moderate to severe psoriasis patients.

Methods

Twelve-week data from a phase II, randomized, double-blind, placebo-controlled, regimen-finding study evaluated HRQoL, measured by the Dermatology Life Quality Index (DLQI). Secukinumab or placebo was administered subcutaneously in three treatment regimens: single (baseline only), monthly (baseline, weeks 4, 8) and early (baseline, weeks 1, 2, 4). Differences among regimens were assessed with logistic regression models and Fisher's exact test.

Results

Patients (n = 404) were randomized to single (baseline) treatment regime

SUBMITTER: Augustin M 

PROVIDER: S-EPMC4814339 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature